MedTrace Logo

Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia

NCT01371968 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-10-27

No results posted yet for this study

Summary

This study aims to determine the optimal dose of alfentanil in suppressing the airway reflexes during supreme LMA removal in anaesthetized adult.

Conditions

  • Airway Response

Interventions

DRUG

alfentanil

Alfentanil is administered intravenously at the end of surgery.

Sponsors & Collaborators

  • Malaysian Society of Anaesthesiologists

    collaborator OTHER

  • University of Malaya

    lead OTHER

Principal Investigators

  • Lee Chew Kiok, MBBS · Department of Anaesthesiogy, UMMC.

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-08-31
Completion
2011-11-30

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01371968 on ClinicalTrials.gov